Clonazepam Recalled Nationwide Over Potentially Life-Threatening Labeling Error

Pharmaceutical company Endo, Inc. has expanded its recall of the anxiety and seizure medication due to mislabeled dosage strength and drug codes.

The U.S. FDA has announced a nationwide recall of 16 lots of Clonazepam Orally Disintegrating Tablets due to mislabeled packaging that could lead to incorrect dosing.
The labeling error, caused by a third-party packager, affects the dosage strength and National Drug Code printed on the cartons, though the blister strips inside are correctly labeled.
Taking an incorrect dose of clonazepam may result in severe side effects, including sedation, confusion, dizziness, and potentially life-threatening respiratory depression, particularly for vulnerable patients.
Endo, Inc., the manufacturer, has reported no adverse events linked to the mislabeled products as of November 21, 2024, and advises consumers to discontinue use of affected lots immediately.
Consumers and retailers are instructed to stop using or distributing the impacted products and contact Inmar, Inc. for returns or further assistance.